ライフサイエンスコーパス: fetuin

1 sialylated biantennary N-glycan derived from fetuin.

2 as precipitation occurred in minutes without fetuin.

3 exhibited markedly reduced binding of BOB93/fetuin.

4 tion of complexes of calcium, phosphate, and fetuin.

5 litated by the negative acute-phase protein, fetuin.

6 ages, or whole glycosylated proteins such as fetuin.

7 f hybrid and complex-type sialoglycoforms of fetuin.

8 the C4-tip using the standard protein bovine fetuin.

9 e identified from a trypsin digest of bovine fetuin.

10 Human fetuin A (HFA) plays a prominent pathophysiological role

11 IA) was developed for the detection of human fetuin A (HFA), a specific biomarker for hepatocellular

12 (IVD) procedure has been developed for human fetuin A (HFA), an important disease biomarker for infla

13 based on monitoring the interactions between fetuin A and NA enzyme.

14 These studies identify fetuin A as a potential extracellular regulator of m-cal

15 n also co-localized with fluorescein-labeled fetuin A at the wound site.

16 the site-specific modification of endogenous fetuin A in human plasma, the synthesis of tandem fluoro

17 Fetuin A increased resealing of scrape-damaged wild-type

18 ar protein kinase C theta activity and serum fetuin A levels.

19 onsistent with the yeast two-hybrid studies, fetuin A neither stabilized mu-calpain nor prevented its

20 The effect of fetuin A on calpain-mediated plasma membrane resealing w

21 Bovine fetuin A stabilized proteolytic activity of purified m-c

22 alpha(2)-Heremans-Schmid glycoprotein (human fetuin A) as a binding partner for calpain domain III (D

23 ast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and biochemical parameters.

24 on and the only macromolecule in solution is fetuin, a 48-kDa inhibitor of apatite growth.

25 ent on the presence of the sialoglycoprotein fetuin, a constituent of bovine serum.

26 rrelated with a 65 to 75% reduction in serum fetuin, a reduction that appears to be caused by the cle

27 Our studies demonstrate that fetuin, a serum glycoprotein that is abundant in the fet

28 core (beta = -0.05, p = 0.0293) but not with fetuin-A (beta = 0.04, p = 0.17).

29 ent analyses were done to define the role of fetuin-A (Fet) in mammary tumorigenesis using the polyom

30 betic patients showed significantly elevated fetuin-A (FetA) levels in respect to their controls; par

31 Functional studies of Fetuin-A (FetA) were conducted by using gene silencing i

32 Plasma fetuin-A (g/l +/- SD) was highest in women using oral es

33 % versus -13.6% versus 9.1%) and increase of fetuin-a (P<0.01).

34 ee consumption was inversely associated with fetuin-A (P-trend = 0.06) and CRP in women and gamma-glu

35 and ferritin (P= 0.0354), and an increase in fetuin-A (P= 0.0024), were observed with secukinumab tre

36 ated on a mineral-rich diet, suggesting that fetuin-A acts to inhibit calcification systemically.

37 Serum fetuin-A also influenced the growth of LLC cells injecte

38 an interorgan communication orchestrated by fetuin-A and adiponectin.

39 significant association was observed between fetuin-A and aortic stenosis (adjusted odds ratio, 1.49;

40 nverse association also was observed between fetuin-A and aortic stenosis among participants without

41 Serum fetuin-A and computed tomography-determined liver fat co

42 ether the association between high levels of fetuin-A and diabetes can be attributed to nonalcoholic

43 nsulin action in animal studies, but data on fetuin-A and diabetes risk in humans are sparse and the

44 s with microRNA and calcification inhibitors fetuin-A and matrix Gla protein suggests a novel role fo

45 anti-mineralization capacity due to reduced fetuin-A and matrix gla-protein (MGP) levels.

46 sease, we observed an inverse association of fetuin-A and mitral annular calcification.

47 The tumor cells adhered to immobilized fetuin-A and not alpha(2)-macroglobulin, its major conta

48 w levels of the calcium-regulating proteins, fetuin-A and osteopontin, have been found in the serum o

49 Interestingly, the tumor cells also took up fetuin-A and secreted it back to the medium using an unk

50 valuated the association between human serum fetuin-A and the metabolic syndrome (MetS) in a cohort o

51 Importantly, anti-fetuin-A antibodies inhibited invasion of hepatocytes by

52 carboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibi

53 These studies support the role of fetuin-A as a major growth promoter in serum that can in

54 mmation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose

55 vidence that the uptake of the serum protein fetuin-A by VSMC is a key event in the inhibition of ves

56 increased coronary artery calcification and fetuin-A can inhibit mineralization of vascular smooth m

57 stochemistry demonstrated that serum-derived fetuin-A co-localized with calcified human vascular smoo

58 ssion construct containing full-length mouse fetuin-A complementary DNA (cDNA), linked to a His-tag,

59 Lower serum fetuin-A concentrations are associated with valvular cal

60 Higher human fetuin-A concentrations are strongly associated with Met

61 e nucleotide polymorphisms (SNPs) related to fetuin-A concentrations by a genome-wide association stu

62 ations of the genetic determinants of plasma fetuin-A concentrations have not been conducted.

63 Mean fetuin-A concentrations were 0.47 +/- 0.10 g/L.

64 Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline.

65 We evaluated the associations among serum fetuin-A concentrations, mitral annular calcification, a

66 t prevalent clinical CVD, we measured plasma fetuin-A concentrations.

67 Participants were categorized by tertiles of fetuin-A concentrations.

68 divided participants into quartiles by serum fetuin-A concentrations.

69 In addition, fetuin-A enhanced phagocytosis of vesicles by VSMC.

70 Mice that lack fetuin-A exhibit extensive soft tissue calcification, wh

71 and bone metastasis samples displayed robust fetuin-A expression, and we demonstrated serum immune re

72 pants (80 of 177) in the highest quartile of fetuin-A had MetS compared with 24% of participants (42

73 th, we showed that LLC tumor cells adhere to fetuin-A in a Ca(2+)-dependent fashion, resulting in gro

74 olonization responded to the levels of serum fetuin-A in a dose-dependent manner, as observed by the

75 tested the hypothesis that overexpression of fetuin-A in Abcc6(-/-) mice counteracts the ectopic mine

76 ctor in circulation, and the serum levels of fetuin-A in patients with PXE as well as in a mouse mode

77 In conclusion, levels of fetuin-A in plasma are strongly associated with SNPs in

78 to our knowledge the first study implicating fetuin-A in prostate cancer and indicating that autoanti

79 together, our data show the significance of fetuin-A in tumor cell growth mechanisms in vitro and op

80 The presence of fetuin-A in vesicles abrogated their ability to nucleate

81 The liver-secreted protein fetuin-A induces peripheral insulin resistance in vitro.

82 To examine the mechanism by which fetuin-A influences LLC colonization and growth, we show

83 Fetuin-A inhibited in vitro VSMC calcification, induced

84 Fetuin-A interferes with insulin action in animal studie

85 However, the processes of fetuin-A intracellular trafficking and MV biogenesis are

86 However, fetuin-A inverted these benign effects of RSFC from an a

87 Fetuin-A is a circulating inhibitor of calcium depositio

88 Fetuin-A is a hepatic secretory protein and a novel risk

89 Fetuin-A is a hepatic secretory protein that binds the i

90 Fetuin-A is a hepatic secretory protein that inhibits ar

91 Fetuin-A is a liver-derived plasma protein involved in t

92 Fetuin-A is a multifunctional hepatic secretory protein

93 Fetuin-A is a multifunctional hepatic secretory protein

94 n cell culture model systems have shown that fetuin-A is a powerful anti-mineralization factor in cir

95 Fetuin-A is a serum glycoprotein in the cystatin family

96 Whereas fetuin-A is an established tumor antigen in several type

97 Higher fetuin-A is associated with incident diabetes mellitus i

98 Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independe

99 Plasma fetuin-A is associated with type 2 diabetes, and AHSG, t

100 Whether fetuin-A is associated with valvular calcification in ot

101 Biochemical studies showed that fetuin-A is essential for the formation of protein-miner

102 models with follow-up through 2012, a higher fetuin-A level was associated with a higher risk of diab

103 d with a 0.06 g/l ( approximately 13%) lower fetuin-A level.

104 1,025 women (median age = 73 years) who had fetuin-A levels and CVD risk factors evaluated in 1992 t

105 sitive association was observed between high fetuin-A levels and diabetes risk: the relative risk (95

106 Lower fetuin-A levels are associated with arterial calcificati

107 Lower fetuin-A levels are independently associated with greate

108 se-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly sel

109 ggest that in the presence of NAFLD elevated fetuin-A levels may impair renal function by RSF-induced

110 Low fetuin-A levels predicted greater risk for CVD mortality

111 tive risk (95% CI) comparing high versus low fetuin-A levels was 1.69 (1.39-2.05) (P for heterogeneit

112 In a pilot study, we observed that higher fetuin-A levels were associated with diabetes mellitus i

113 or cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance.

114 Lower fetuin-A levels were associated with older age, but with

115 These findings suggest that plasma fetuin-A levels were independently associated with highe

116 Fetuin-A levels were inversely associated with CAC sever

117 We examined the association of fetuin-A levels with approximately 2.5 million genotyped

118 s to evaluate the prospective association of fetuin-A levels with cardiovascular disease (CVD) mortal

119 Participants with fetuin-A levels within the highest tertile (> 0.97 g/L)

120 iant alone explained 14% of the variation in fetuin-A levels.

121 s many colonies in mice heterozygous for the fetuin-A locus compared with homozygous WT mice and rest

122 vo study we hypothesized that the hepatokine fetuin-A may impair renal function in non alcoholic fatt

123 at maintaining normal circulating levels of fetuin-A may prove beneficial in patients with ESRD.

124 Fetuin-A may provide novel insight into mechanisms leadi

125 Fetuin-A may represent an important inhibitor of dystrop

126 If confirmed, fetuin-A might mark calcium deposition within the vascul

127 ecting Lewis lung carcinoma (LLC) cells into fetuin-A null and their wild-type (WT) littermate contro

128 o the lungs within 2 weeks in the WT but not fetuin-A null mice.

129 metastatic nodules, whereas the lungs of the fetuin-A null mutant mice were virtually free of colonie

130 extracellular region of TRAP interacts with fetuin-A on hepatocyte membranes and that this interacti

131 Future studies should evaluate whether fetuin-A predicts coronary artery disease risk.

132 ratio for CVD mortality comparing the lowest fetuin-A quartile with all higher values was 1.76 (95% c

133 Higher fetuin-A quartiles were also strongly and independently

134 e odds ratio (OR) (95% CI) comparing extreme fetuin-A quintiles was 1.81 (1.07-3.06) (P for trend = 0

135 indicating that autoantibodies specific for fetuin-A show utility as a prognostic indicator for pros

136 ous calcification in vivo, the serum protein fetuin-A stabilizes calcium and phosphate into 70-100 nm

137 g participants without diabetes, the highest fetuin-A tertile had a significantly lower odds of aorti

138 Those within the highest fetuin-A tertile had significantly lower odds of mitral

139 lonization by the administration of purified fetuin-A to fetuin-A-null mice.

140 Addition of fetuin-A to the culture system prevented the mineralizat

141 The attachment of tumor cells to fetuin-A was accompanied by phosphatidylinositol 3-kinas

142 Each 0.10-g/L (SD)-greater fetuin-A was associated with 19 higher risk of diabetes

143 ordinal logistic regression, each SD higher fetuin-A was associated with 31% lower odds of CAC sever

144 The interaction of cells with fetuin-A was driven mainly by Ca(2+) ions, and cells gro

145 were expressed locally in vibrissae, whereas fetuin-A was expressed highly in the liver.

146 Alexa488-labeled fetuin-A was internalized by human VSMCs, trafficked via

147 tron microscopy-immunogold demonstrated that fetuin-A was internalized by VSMC and concentrated in in

148 f age without diabetes mellitus at baseline, fetuin-A was measured in serum collected in 1992 to 1993

149 In contrast, no association of fetuin-A was observed with PAD or high common or interna

150 Subsequently, fetuin-A was secreted via vesicle release from apoptotic

151 (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in fasting blood samples and th

152 Levels of fetuin-A were slightly decreased in Abcc6-/- serum, and

153 In contrast, the association of fetuin-A with aortic stenosis was modified by the presen

154 d we demonstrated serum immune reactivity to fetuin-A with concomitant development of metastatic cast

155 The association of fetuin-A with CVD mortality differed by diabetes status

156 bserved a particularly strong association of fetuin-A with diabetes risk in women that could not be e

157 We sought to confirm the association of fetuin-A with incident diabetes mellitus in older person

158 gression models evaluated the association of fetuin-A with incident diabetes mellitus.

159 However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unkno

160 No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or

161 is study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD) i

162 The association of fetuin-A with subclinical CVD in the general population

163 One of them is fetuin-A, a 60-kDa glycoprotein synthesized in the liver

164 Dialysis patients with low levels of serum fetuin-A, a circulating inhibitor of mineralization, hav

165 bound to alpha2-Heremans-Schmid glycoprotein/fetuin-A, a hepatocyte-specific protein associated with

166 form the first nidus for mineralization and fetuin-A, a potent circulating inhibitor of calcificatio

167 ound that both the sera of mice deficient in fetuin-A, a serum protein that inhibits calcification, a

168 ses' Health Study, for whom levels of plasma fetuin-A, alanine transaminase (ALT), and gamma-glutamyl

169 other desaturase-associated biomarkers (CRP, fetuin-A, ALT, and GGT) did not lead to appreciable atte

170 immunostaining for matrix-gla-protein (MGP), fetuin-A, and ankylosis protein (Ank) as well as alkalin

171 ification in body fluids, including albumin, fetuin-A, and apolipoprotein A1.

172 icles containing the serum proteins albumin, fetuin-A, and apolipoprotein A1; the mineralization-asso

173 PAD was measured concurrent with fetuin-A, and CAC and cIMT were measured 4.6 years (mean

174 -molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured

175 ers (reflected by gamma-glutamyltransferase, fetuin-A, and sex hormone-binding globulin), markers of

176 ansferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-based fatty liver index (FLI

177 rum and exosome proteins, including albumin, fetuin-A, apolipoprotein-A1, alkaline phosphatase, TNFR1

178 Schmid glycoprotein, commonly referred to as fetuin-A, are reduced in ESRD, a condition associated wi

179 iponectin, resistin, liver function enzymes, fetuin-A, body composition, pancreatic fat, intramyocell

180 results suggest that normalization of serum fetuin-A, either through gene therapy approaches or by d

181 type 2 diabetes, and AHSG, the gene encoding fetuin-A, has been identified as a susceptibility locus

182 rough distinct molecular mechanisms, such as fetuin-A, osteopontin, and bone morphogenic protein 7, a

183 d bone osteoclastic activity, and lower free fetuin-A, plasma pyrophosphate, and albumin concentratio

184 To study effects of the crosstalk between fetuin-A, RSF and kidney, human renal sinus fat cells (R

185 In the present analyses, we showed that fetuin-A, whose function in cellular attachment in tissu

186 protein fraction was immunoprecipitated on a fetuin-A-adsorbed protein A column, TRAP bound this liga

187 We could demonstrate that fetuin-A-containing CPPs facilitate the clearance of min

188 In mice, fetuin-A-containing CPPs were rapidly cleared by the ret

189 r, onset of malaria infection was delayed in fetuin-A-deficient mice compared to that in wild-type C5

190 enced the growth of LLC cells injected s.c.: fetuin-A-null mice developed small s.c. tumors only afte

191 y the administration of purified fetuin-A to fetuin-A-null mice.

192 ha, IL-6, IL-12, IL-17, malondialdehyde, and fetuin-a.

193 hment was confined to the fractions that had fetuin-A.

194 xtracellular Ca(2+) ions as cells growing in fetuin-A.

195 in-A6, one of the cell surface receptors for fetuin-A.

196 -Heremans-Schmid glycoprotein, also known as fetuin-A.

197 rying two null alleles for the gene encoding fetuin, Ahsg (B6, 129-Ahsg(tm1Mbl)).

198 model glycoproteins included ribonuclease B, fetuin, alpha(1)-acid glycoprotein, immunoglobulin, and

199 Retrocyclin also bound fetuin, an extensively glycosylated protein, with high a

200 ter etidronate injection, and the FMC is 46% fetuin and 53% mineral by mass.

201 ified HA1 oligomers (but not monomers) bound fetuin and agglutinated red blood cells.

202 well on microtiter wells in the presence of fetuin and divalent ions in a carbohydrate-dependent man

203 wn for phosphorylation analysis using bovine fetuin and glycosylation analysis using bovine ribonucle

204 levels of binding to sialylated moieties on fetuin and GPIbalpha.

205 ne ribonuclease B, human transferrin, bovine fetuin and human alpha1-acid glycoprotein, the correspon

206 ing well-characterized N-glycans from bovine fetuin and IgG from human serum.

207 f calcium phosphate mineral and the proteins fetuin and matrix Gla protein (MGP) that was initially d

208 f calcium phosphate mineral and the proteins fetuin and matrix Gla protein that was initially discove

209 orted calcification inhibitory activities of fetuin and MGP may be related to their ability to form s

210 ilar in domain structure to fetuin and, like fetuin and MGP, contains several residues of phosphoseri

211 se observations suggest that spp24 may, like fetuin and MGP, play a role in inhibiting calcification.

212 n was tested on glycans released from bovine fetuin and model glycoprotein mixtures (RNase B, bovine

213 f two potential glycoprotein cancer markers, fetuin and prostate-specific antigen (PSA), with 10 min

214 d by first comparing N-glycans isolated from fetuin and serum and was then exploited to analyze the e

215 CdtA-II(Ec) and CdtC-II(Ec) bind immobilized fetuin and thyroglobulin as well as fucose and to a less

216 al of N- but not O-linked carbohydrates from fetuin and thyroglobulin prevents binding of CdtA-II(Ec)

217 Da protein is similar in domain structure to fetuin and, like fetuin and MGP, contains several residu

218 l complex consists of about 18% mineral, 80% fetuin, and 2% matrix Gla protein (MGP) by weight, and t

219 ed proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.

220 proteins including chicken ovalbumin, bovine fetuin, and horseradish peroxidase (HRP) were digested b

221 Model glycoproteins (bovine RNase B, bovine fetuin, and human IgG) and a complex mixture from human

222 model glycoprotein mixtures (RNase B, bovine fetuin, and IgG) with good linearity (R(2) = 0.9884) and

223 trix gamma-carboxyglutamic acid Gla protein, fetuin, and osteopontin, also contribute to vascular cal

224 the glycoproteins alpha1-acid glycoprotein, fetuin, and ribonuclease B, as well as from glycoprotein

225 ycans derived from alpha1-acid glycoprotein, fetuin, and ribonuclease B.

226 trategies using standard glycoproteins (IgG, fetuin, and RNase B) and featured rapid processing time,

227 tylia mollis is a lectin with high finity to fetuin, and used here to differentiate prostate cancer a

228 osaccharide mass has been demonstrated using fetuin as a model compound.

229 We successfully used fetuin as a model protein to test the feasibility of thi

230 ptimized our automated protocol using bovine fetuin as a standard glycoprotein, and then assessed the

231 With the use of bovine fetuin as a standard glycoprotein, the incubation time w

232 The assay used bovine fetuin as an internal standard and a two-dimensional sol

233 ovine RNase B, human transferrin, and bovine fetuin as models to demonstrate the feasibility of the m

234 ferent glycan types was studied using bovine fetuin, asialofetuin, IgG, ribonuclease B, and alpha-1 a

235 on six model glycoproteins (RNase B, avidin, fetuin, asialofetuin, transferrin, and AGP) as well as a

236 Using bovine fetuin (because it contains the sialylated O-glycans mos

237 lycoproteins were analyzed, including bovine fetuin, bovine submaxillary gland mucin, and serum immun

238 ed in Pichia pastoris, hen ovalbumin, bovine fetuin, bovine thyroglobulin, and several invertase prep

239 and GuHCl-induced unfolding of bovine serum fetuin (BSF) has been studied by differential scanning c

240 cells with glycoproteins (thyroglobulin and fetuin), but not simple sugars, blocks surface binding o

241 MC in the 9-24-h interval lowers total serum fetuin by 50%.

242 for a receptor-mediated uptake mechanism for fetuin by cultured human VSMCs.

243 These observations suggest that the fetuin component of the FMC is derived from fetuin initi

244 etidronate injection does not increase serum fetuin despite the fact that 50% of serum fetuin is asso

245 periments with this system demonstrated that fetuin determines the location of mineral growth; in the

246 Common O-linked sugar chains found in fetuin, equine chorionic gonadotropin, and glycophorin c

247 c (Galbeta1-4GlcNAc) and TF-antigen, and (3) fetuin (FET), the sialylated glycoform of ASF.

248 is the antigen for BOB93, and that BOB93 and fetuin form a complex in solution that is necessary and

249 clearance of the FMC removes the associated fetuin from circulation.

250 The fetuin gene (AHSG) is located on human chromosome 3q27,

251 Tandem spectra of glycopeptides from fetuin, glycophorin A, ovalbumin and gp120 tryptic diges

252 biomarkers of cancer has studied the role of fetuin glycoprotein on the metastatic disease diagnosis.

253 Experiments with glycosidase-treated fetuin, gp120, and CD4 revealed that both O-linked and N

254 The electrode analytical response to fetuin in PBS samples, obtained by square wave voltammet

255 We tested the role of systemic fetuin in tumor cell growth and metastasis by injecting

256 Purified bovine fetuin inhibited the precipitation of mineral for over 1

257 Additionally, asialofetuin, not fetuin, inhibited platelet phagocytosis suggesting the i

258 Fetuin inhibits insulin-induced insulin receptor (IR) au

259 fetuin component of the FMC is derived from fetuin initially in serum and that clearance of the FMC

260 The data suggest that fetuin is a natural modulator of galectin-3 secretion/re

261 Additional experiments showed that fetuin is also able to localize calcification to the int

262 um fetuin despite the fact that 50% of serum fetuin is associated with the FMC, and clearance of the

263 We demonstrate that fetuin is the antigen for BOB93, and that BOB93 and fetu

264 s, as well as N-linked glycans released from fetuin, is used to demonstrate the utility of the tetrap

265 Fetuin knockout (KO) mice demonstrate increased basal an

266 When fed a high-fat diet, fetuin KO mice are resistant to weight gain, demonstrate

267 Glucose and insulin tolerance tests in fetuin KO mice indicate significantly enhanced glucose c

268 Fetuin KO mice subjected to euglycemic-hyperinsulinemic

269 These data suggest that fetuin may play a significant role in regulating postpra

270 This highly specific complex of fetuin, MGP, and mineral prevents the growth, aggregatio

271 cation of mineral growth; in the presence of fetuin mineral grows exclusively within the fibril, wher

272 nt study was carried out to characterize the fetuin-mineral complex (FMC), a high molecular mass comp

273 th results indicate that serum levels of the fetuin-mineral complex are indeed associated with vitami

274 One possibility is that high levels of the fetuin-mineral complex cause defects in the ability of f

275 found at 24 h to 14 days is identical to the fetuin-mineral complex found in the serum of etidronate-

276 appears to be caused by the clearance of the fetuin-mineral complex from serum.

277 ible association between the presence of the fetuin-mineral complex in serum and vitamin D-induced ar

278 D for 96 h, and that there is no detectable fetuin-mineral complex in the blood of rats in which art

279 The first experiment shows that there is a fetuin-mineral complex in the blood of rats in which ext

280 ative agent, and that the serum level of the fetuin-mineral complex is a marker for the activity of t

281 Another possibility is that the fetuin-mineral complex is the downstream product of a pa

282 the timing of the maximal increase in serum fetuin-mineral complex levels.

283 Large amounts of the fetuin-mineral complex were generated in the first 3 h o

284 vitro is accompanied by the formation of the fetuin-mineral complex, a high molecular mass complex of

285 oligosaccharides, including NCAM N-glycans, fetuin N-glycans, synthetic sialylated N-acetyllactosami

286 I or IV or to the negative control proteins fetuin or bovine serum albumin.

287 ther than basic, showed no binding to either fetuin or GPIbalpha.

288 linked oligosaccharides released from bovine fetuin, polyclonal human serum immunoglobulin G (IgG), a

289 Fetuin purified from the FMC contains 3.3 mol of protein

290 The addition of calcium chloride to fetuin resulted in an increase in peeling, whereas subse

291 Fetuin, shown by mass spectrometry not to contain MGP, w

292 was a biphasic drop in ionic calcium in the fetuin solution, however, from 5 to 3 mM in the first ho

293 4) A large protein (fetuin) that selectively inhibits growth of crystals rem

294 show that the previously reported ability of fetuin to inhibit the precipitation of hydroxyapatite fr

295 eral complex cause defects in the ability of fetuin to prevent the growth of the mineral component, w

296 r (Galbeta1,3GalNAcbeta1,3Galalpha-O-Me) and fetuin triantennary asialoglycopeptide.

297 Fetuin uptake and secretion by proliferating and differe

298 Bovine fetuin was used as a model glycoprotein in this study.

299 methodology using the standard glycoprotein, fetuin, we investigated normal urine samples to obtain N

300 to a well characterized glycoprotein bovine fetuin with both N- and O-linked glycans and a highly gl